Please check your internet connection and try again.
# Linagliptin
## Overview
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone concentrations, stimulating glucose-dependent insulin release and decreasing glucagon secretion. It is pharmacokinetically unique among DPP-4 inhibitors due to its primarily non-renal route of elimination.
## Primary Indications
* Type 2 Diabetes Mellitus (T2DM) as an adjunct to diet and exercise to improve glycemic control.
## Adult Dosing
* **Standard Dose:** 5 mg orally once daily.
* **Maximum Dose:** 5 mg daily.
## Pediatric Dosing
* **Safety and Efficacy:** Not established in patients <18 years. Use is generally avoided in the pediatric population based on current labels.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment necessary. Linagliptin is extensively excreted via the bile and gut; only a small fraction is cleared renally.
* **Hepatic Impairment:** No dose adjustment necessary.
## Contraindications
* History of hypersensitivity reaction (e.g., anaphylaxis, angioedema, exfoliative skin conditions) to linagliptin.
* Type 1 Diabetes Mellitus or treatment of diabetic ketoacidosis.
## Adverse Effects
* **Common:** Nasopharyngitis, hypoglycemia (when used with insulin or secretagogues).
* **Serious:** Acute pancreatitis (discontinue if suspected), severe and disabling arthralgia, bullous pemphigoid, and hypersensitivity reactions.
## Key Drug Interactions
* **Strong CYP3A4 or P-glycoprotein Inducers (e.g., Rifampin):** May decrease linagliptin efficacy. Avoid co-administration if possible.
* **Secretagogues/Insulin:** Increases risk of hypoglycemia; a lower dose of the concomitant insulin or sulfonylurea may be required.
## Monitoring
* **HbA1c:** Every 3–6 months.
* **Renal Function:** While dose adjustment is not required, renal function assessment is standard care in T2DM.
* **Clinical:** Observe for signs/symptoms of pancreatitis (severe abdominal pain, vomiting) and severe joint pain.
## Clinical Pearls
* **Formulation:** Tablets can be taken with or without food.
* **No Hepatic/Renal Dosing:** Its primary biliary excretion profile makes it a favorable option for patients with comorbid chronic kidney disease or dialysis dependence, unlike other gliptins.
* **Weight Neutrality:** Generally weight-neutral; lacks the weight-loss benefits associated with GLP-1 receptor agonists or SGLT2 inhibitors.
* **Dual Therapy:** Often combined with metformin or SGLT2 inhibitors for synergistic glycemic control.
***
**Educational Disclaimer:** This information is for educational purposes only and does not constitute medical advice. Always verify current prescribing information, institutional protocols, and specific patient contraindications through clinical resources like Lexicomp, UpToDate, or the manufacturer’s package insert before prescribing or administering medication.
